<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753517</url>
  </required_header>
  <id_info>
    <org_study_id>2014_02</org_study_id>
    <secondary_id>2014-A01685-42</secondary_id>
    <nct_id>NCT02753517</nct_id>
  </id_info>
  <brief_title>Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies</brief_title>
  <acronym>SCINTIVOL</acronym>
  <official_title>Predictive Value of Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies Stretches of 4 or More Segments on Non-cirrhotic Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extended hepatectomies of 4 or more segments are complicated by high rates of morbidity and
      mortality, mainly related to hepatic liver failure. Nowadays, preoperative assessment of the
      future remnant liver is just performed through its volumetric measurement by computed
      tomography. Nevertheless, this volumetric assessment does not reflect the hepatocellular
      function of the future remnant liver that can be disturbed in case of vascular and/or biliary
      obstruction, chemotherapy-induced liver injuries or steatosis in overweight patients.
      Literature data (albeit originating from a single centre in Europe) have suggested that
      (99m)Tc-mebrofenin hepatobiliary scintigraphy could be useful in evaluating the function of
      the future remnant liver. The aim of this prospective multicentric study is to determine the
      predictive value of hepatobiliary scintigraphy in assessing the risk of postoperative liver
      failure of extended hepatectomies of 4 or more segments in noncirrhotic liver.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main aim of the study is to determine the predictive value of (99m)Tc-mebrofenin
      hepatobiliary scintigraphy in assessing the postoperative risk of liver failure within 3
      months of extended hepatectomy of 4 or more segments in noncirrhotic liver. The main endpoint
      is the three-months postoperative liver failure, defined as an increased International
      Normalized Ratio (INR) and concomitant hyperbilirubinemia (according to the normal limits of
      the local laboratory) on or after postoperative day 5 according to the international
      classification of the ISGLS (International Study Group of Liver Surgery) and classified
      according to its severity in grade A (no change of the patient's clinical management), grade
      B (deviation from the regular course but without invasive therapy) and grade C (invasive
      treatment)

      Secondary objectives are:

      To determine the predictive value of (99m)Tc-mebrofenin hepatobiliary scintigraphy in
      assessing the risk of postoperative morbi-mortality (according to Clavien-Dindo
      classification) within 3 months of extended hepatectomy of 4 or more segments in noncirrhotic
      liver, and the duration of intensive care unit stay and of hospitalization.

        -  To assess the correlation between the results of the hepatobiliary scintigraphy and the
           presence of parenchymal abnormalities such as steatosis, fibrosis or
           chemotherapy-induced injuries (sinusoidal obstruction syndrome, steatohepatitis) at the
           histological analysis of the non tumoral liver parenchyma.

        -  To assess the sensitivity of hepatobiliary scintigraphy in jaundiced patients who had a
           preoperative biliary endoscopic or radiologic drainage, considering the existing
           competition between mebrofenin and bilirubin on hepatic receptors.

        -  To analyse the inter-centre reproducibility of the hepatobiliary scintigraphy (Central
           review by the principal investigator of 25 scintigraphy examinations per centre)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2015</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic insufficiency</measure>
    <time_frame>at 3 months</time_frame>
    <description>ISGLS criteria : a definition and grading by the International Study Group of Liver Surgery (ISGLS)of the Posthepatectomy liver failure:</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative morbi-mortality</measure>
    <time_frame>at 3 months</time_frame>
    <description>Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of intensive care unit stay and of hospitalization</measure>
    <time_frame>3 months</time_frame>
    <description>Duration of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological analysis of the non tumoral liver parenchyma</measure>
    <time_frame>at 3 months</time_frame>
    <description>correlation of liver parenchymal abnormalities with the results of scintigraphy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-centre reproducibility of the hepatobiliary scintigraphy</measure>
    <time_frame>at 3 months</time_frame>
    <description>Central review by the principal investigator of 25 scintigraphy examinations per centre</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hepatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>Extended hepatectomy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hepatic Scintigraphy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hepatobiliary scintigraphy</intervention_name>
    <description>hepatobiliary scintigraphy with functional assessment of the future remnant liver before an extended hepatectomy of 4 or more segments</description>
    <arm_group_label>Extended hepatectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Noncirrhotic liver

          -  Benign or malignant liver tumor

          -  Anatomic hepatic resection ≥ 4 segments

          -  Aged ≥18

          -  ASA Score ≤3

          -  Signed informed consent

          -  Presence of contraception in non-menopausal women

        Exclusion Criteria:

          -  Cirrhosis

          -  Absence of preoperative biliary drainage in case of preoperative jaundice

          -  Patient refusal

          -  Absence of affiliation to Social Security

          -  Body weight above 230kg

          -  Known allergy to Hida derivatives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphanie Truant, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphanie Truant, MD</last_name>
    <email>stephanie.truant@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Nord, CHU</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Marc REGIMBEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurence CHICHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian LETOUBLON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU, Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stéphanie Truant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean HARDWIGSEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HPHôpital Beaujon,</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier FARGES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lilian SCHWARZ Lilian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fabrice MUSCARI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Bennink RJ, Tulchinsky M, de Graaf W, Kadry Z, van Gulik TM. Liver function testing with nuclear medicine techniques is coming of age. Semin Nucl Med. 2012 Mar;42(2):124-37. doi: 10.1053/j.semnuclmed.2011.10.003. Review.</citation>
    <PMID>22293167</PMID>
  </results_reference>
  <results_reference>
    <citation>de Graaf W, Heger M, Spruijt O, Maas A, de Bruin K, Hoekstra R, Bennink RJ, van Gulik TM. Quantitative assessment of liver function after ischemia-reperfusion injury and partial hepatectomy in rats. J Surg Res. 2012 Jan;172(1):85-94. doi: 10.1016/j.jss.2010.06.038. Epub 2010 Jul 21.</citation>
    <PMID>20869070</PMID>
  </results_reference>
  <results_reference>
    <citation>de Graaf W, Bennink RJ, Veteläinen R, van Gulik TM. Nuclear imaging techniques for the assessment of hepatic function in liver surgery and transplantation. J Nucl Med. 2010 May;51(5):742-52. doi: 10.2967/jnumed.109.069435. Epub 2010 Apr 15. Review.</citation>
    <PMID>20395336</PMID>
  </results_reference>
  <results_reference>
    <citation>de Graaf W, Häusler S, Heger M, van Ginhoven TM, van Cappellen G, Bennink RJ, Kullak-Ublick GA, Hesselmann R, van Gulik TM, Stieger B. Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol. 2011 Apr;54(4):738-45. doi: 10.1016/j.jhep.2010.07.047. Epub 2010 Oct 1.</citation>
    <PMID>21163547</PMID>
  </results_reference>
  <results_reference>
    <citation>de Graaf W, van Lienden KP, van den Esschert JW, Bennink RJ, van Gulik TM. Increase in future remnant liver function after preoperative portal vein embolization. Br J Surg. 2011 Jun;98(6):825-34. doi: 10.1002/bjs.7456. Epub 2011 Apr 11.</citation>
    <PMID>21484773</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatobiliary scintigraphy</keyword>
  <keyword>extended hepatectomy</keyword>
  <keyword>volumetry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

